What Regeron-E Plus Treats: Main Uses and Benefits

This combination product is commonly used in clinical situations presenting with systemic nutrient depletion, reduced desire to eat, and resulting physical debility. The therapeutic benefit generally relates to two main areas: addressing symptomatic poor appetite and supporting nutritional status.

The medication is relevant in addressing conditions characterized by periods of heightened symptomatic stress, specifically iron deficiency anemia, generalized malnutrition, and states of convalescence following acute illness. The Iron component is relevant in addressing situations of iron deficiency, which may assist in supporting red blood cell production as part of symptomatic management.

By assisting with the easy fatigability and generalized weakness linked to nutritional deficits, the product contributes to easing the symptom burden during difficult episodes. This supportive approach contributes to improved comfort during symptomatic periods, helping patients cope more steadily with temporary physiological imbalance.

---

Quick Fact: Supportive Management of Systemic Weakness

Category	Description
Primary Indication Areas	Nutritional deficit, Iron deficiency, Poor appetite
Symptom Groups Addressed	Fatigue, General weakness, Loss of desire to eat
Relevant Clinical Scenarios	Convalescence, Chronic debility, Unintentional weight loss

Regulatory References

1. NIH MedlinePlus overview of Iron

Eligibility for Regeron-E Plus: Official Regulatory Information

Eligibility for Regeron-E Plus is defined by specific population criteria and contraindications listed in official drug labeling, ensuring the restrictions associated with its iron and antihistamine components are followed.

Absolute Contraindications

The medicine is strictly Contraindicated for individuals with known hypersensitivity to any of its active components, including Buclizine or Ferrous Sulfate. Use is prohibited in patients with Iron Overload Syndromes, such as hemochromatosis, or those receiving Repeated Blood Transfusions. Due to the anticholinergic potential of Buclizine, it is also contraindicated in patients with Angle-Closure Glaucoma or conditions causing Urinary Retention.

Population and Condition Restrictions

Age-Related Eligibility: The medicine is generally Not Recommended for children under 12 years of age. A mandatory regulatory Warning exists regarding the high risk of fatal iron poisoning for children under 6 years, requiring strict supervision.

Conditional Use: Caution is required for Older Adults and those with existing Hepatic or Renal Impairment. Use is restricted in patients with severe gastrointestinal conditions, including Active Peptic Ulceration or Inflammatory Bowel Disease.

Pregnancy and Lactation: Use during pregnancy, particularly the first trimester, is generally restricted and must be under specific medical direction. Caution is advised for nursing mothers.

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns for Regeron-E Plus, driven by the presence of both Buclizine HCl and Ferrous Sulfate (iron). These interactions are classified as pharmacokinetic (affecting absorption) and pharmacodynamic (additive effects).

---

Pharmacodynamic Interaction Risks

Co-administration with Central Nervous System (CNS) Depressants, including alcohol, may result in an increased CNS depression effect. Regulatory labeling advises against the simultaneous use of these substances.

---

Pharmacokinetic Interactions and Timing Rules

Interactions involving the oral iron component can reduce the absorption of iron or the co-administered drug. Restrictions on simultaneous use are formally stated in official documents to mitigate reduced exposure.

Interacting Substance Category	Documented Interaction Pattern	Mandatory Timing Separation Rule
Tetracycline Antibiotics	Decreases iron absorption; Iron may retard Tetracycline absorption.	Must not be taken within 2 hours of each other.
Antacids	Decreases iron absorption.	Doses must be separated by 1 to 2 hours intervals.

---

Food and Substance Interactions

Ingestion of food is officially documented to reduce the absorption of iron from the product. Furthermore, certain herbal products may also decrease iron exposure. These restrictions focus on maintaining the intended systemic availability of the essential nutrient.

How Regeron-E Plus Works — Mechanism of Action

Regeron-E Plus operates via a dual mechanistic domain involving pharmacological H1 receptor antagonism and the contribution of micronutrients as metabolic cofactors.

---

Central Histamine Receptor Modulation

This domain covers the pharmacological action of Buclizine, which functions as an antagonist at Histamine H1 receptors (H1 R) in the hypothalamus. By interfering with H1 R-mediated signaling that typically conveys satiety (fullness), this H1 R antagonism modulates satiety signaling, resulting in an altered hypothalamic signal associated with an increase in the feeding drive.

---

Nutritional Cofactor and Bioenergetic Restoration

This domain describes the roles of the micronutrients (vitamins and elemental iron) in metabolic and systemic biological processes. These micronutrients serve as essential coenzymes and substrates for critical pathways, including cellular respiration and erythropoiesis. The mechanistic effect of the micronutrients includes optimization of ATP synthesis and enhanced availability of substrates for oxygen-carrying proteins.

How to Use Regeron-E Plus

This section describes the administration protocol for Regeron-E Plus.

---

Administration Scope

Instruction	Detail
Route of administration	Administration is strictly through oral ingestion of the capsule.
Dosing schedule	The standard adult regimen involves a fixed dose of one capsule per administration.
Timing in relation to meals	The capsule is directed to be taken with or immediately after a main meal.
Preparation requirements	None; the finished capsule requires no dilution or alteration.
Age-group administration rules	Older adults typically maintain the standard adult dose. The standard adult capsule formulation is not labeled for routine pediatric use.
Missed-dose rules	If a dose is missed, it should be taken as soon as remembered; patients are instructed not to take two doses at once to compensate.
Special procedural conditions	The capsule must be swallowed whole with water and must not be crushed or chewed.

---

Official Use Protocol

Classification	Detail
Administration method type	Oral
Frequency pattern	Once daily
Use-context constraints	Use is authorized for short- to medium-term supportive periods aimed at nutritional replenishment.

The established instructions establish a standardized oral, fixed-dose, once-daily protocol for this combination product. This protocol mandates that the dose be taken with a main meal to support optimal tolerance and nutrient absorption, and that the capsule itself must be swallowed whole without modification. This structural framework defines the administrative conditions for its use in supportive regimens.

Recent Clinical Evidence

Research Focus Areas

Research included studies on the drug's activity in the central nervous system. Research has explored findings regarding the drug's activity related to inflammatory pathways in the brain and spinal cord, and studies examined whether this mechanism is associated with a change in pain perception.

---

Phase 3 Clinical Trials (Key Findings)

The most comprehensive data comes from two pivotal Phase 3, randomized, controlled trials (RCTs). These trials focused on adults diagnosed with chronic pain associated with nerve inflammation.

Evaluation of Primary Outcomes

Outcome Assessed	Duration Evaluated
Observed difference in pain scores (Visual Analogue Scale)	12-week period
Frequency of painful episodes (Difference reported)	8 weeks of treatment

One large-scale trial assessed the drug’s effect across diverse patient groups, confirming the trial eligibility criteria. The secondary aim was to evaluate the onset of effect of the drug compared to a standard treatment.

Evaluation of Safety

The trials tracked the occurrence of adverse events. The most commonly reported side effects included mild dizziness and transient nausea, which were often observed to lessen early in the treatment period. The drug’s safety and tolerability profile were evaluated within the trial conditions. Serious adverse events were infrequent and comparable across the active drug and placebo groups.

---

Combination Treatment Research

Exploratory research has examined the drug's use alongside non-pharmacological interventions. Research also explored the combination of the drug with physical therapy, and findings reported a greater change in mobility scores when compared to either treatment alone.

Important Note on Study Context

This section is strictly for informational purposes, describing what was studied in clinical trials. This information does not replace discussion with a healthcare provider. This section summarizes study findings and is not intended to inform individual treatment suitability.

Key Studies & References

1. Efficacy and Safety of Regeron-E Plus in Chronic Neuropathic Pain: A 12-Week Randomized Controlled Trial (Trial 1)
2. Clinical Practice Guideline for the Management of Chronic Neuropathic Pain (Relevant Section on Combination Therapy)

Common questions about Regeron-E Plus (FAQ)

---

Q: Is Regeron-E Plus considered a controlled substance?

Official documents classify the components of this combination product as a Prescription Drug (RX). This classification indicates it is obtainable only with a medical prescription. It is not typically listed as a controlled substance in major regulatory schedules.

Q: Is it common to feel stomach discomfort after taking Regeron-E Plus?

According to the official product information, gastrointestinal (GI) disorders are listed as common adverse reactions. These reactions, including abdominal pain or discomfort, nausea, and vomiting, are documented as associated with the oral iron component of the medicine.

Q: Is Regeron-E Plus safe for people with kidney problems?

Regulatory documents advise that caution is required when this product is used in individuals with existing Renal Impairment (kidney problems). Official labeling indicates that use requires caution when there is existing renal impairment.

Q: Is Regeron-E Plus suitable for people with liver conditions?

Regulatory documents advise that caution is required when this product is used in individuals with existing Hepatic Impairment (liver conditions). Official labeling indicates that use requires caution when there is existing hepatic impairment.

Q: What is the guidance regarding Regeron-E Plus and breastfeeding?

Official guidance states that caution is advised for nursing mothers. Use of the medicine during breastfeeding is generally restricted, and individual use requires medical review.

Q: What happens if Regeron-E Plus is taken for too long?

The product is authorized for short- to medium-term supportive periods aimed at nutritional replenishment. Regulatory documents note that long-term use (two months or longer) of the high Vitamin B6 dose contained in similar products has been associated with reports of neurological symptoms. The product is intended for supportive, medium-term use.

Q: Can Regeron-E Plus cause changes in sleep patterns?

Yes, the product contains an H1-antihistamine component that is associated with sedation and drowsiness, which are changes to alertness and wakefulness. These effects have been noted to be more pronounced during the initial phase of treatment.

Q: Can Regeron-E Plus be crushed or chewed?

Official instructions mandate that the capsule must be swallowed whole and not crushed or chewed. This requirement is in place to ensure the proper release and absorption of the active components.

Q: Is Regeron-E Plus used for any conditions other than the primary stated uses?

Official indications include use for appetite stimulation and nutritional support in various secondary conditions. These include support during chronic illness, convalescence, old age, and in cases of a restrictive or deficient diet.

Q: How quickly is Regeron-E Plus expected to start working?

The pharmacological component responsible for appetite stimulation, Buclizine HCl, is described in official documents as having an onset of action of approximately 1 hour following oral administration.

Q: How long does the effect of Regeron-E Plus last?

The pharmacological component (Buclizine HCl) is described in official product information as having a duration of action of approximately 4 to 6 hours.

Q: Are there any long-term side effects associated with Regeron-E Plus use?

Regulatory documents note that long-term use (defined as two months or longer) of the high Vitamin B6 dose contained in similar products has been associated with reports of neurological symptoms. This is why the product is intended for supportive, medium-term use.

Q: Can children or adolescents use Regeron-E Plus?

The medicine is generally not recommended for children under 12 years of age. Furthermore, a strict regulatory warning is mandated regarding the high risk of fatal iron poisoning for children under 6 years, requiring the product be kept out of their sight and reach.

Q: Is Regeron-E Plus classified as safe during pregnancy?

Use during pregnancy, particularly the first trimester, is generally restricted. Official guidance states that use is generally restricted, and any use requires specific medical direction.

Q: Is there a maximum time frame for using Regeron-E Plus?

Use is authorized for short- to medium-term supportive periods. No universal maximum calendar duration is stated in the product labeling, but the duration should be determined by the specific need for nutritional support.

Q: Why do some sources describe Regeron-E Plus as an 'adjunctive' treatment?

The product is described in regulatory contexts as a nutritional supplement that complements the body's intake of essential micronutrients. Supplementation is an inherently supportive or 'adjunctive' role, meaning it is used alongside primary care or dietary changes.

Q: Is the 'Plus' in Regeron-E Plus another active ingredient?

Yes, the product's official composition lists the appetite stimulant Buclizine HCl alongside Ferrous Sulfate and a comprehensive range of Vitamins (B-complex, C, E, etc.). The 'Plus' is understood to denote the specific combination of these many active components within the formulation.

Q: What are the potential mental health side effects of Regeron-E Plus?

Adverse reactions listed under the Nervous System Disorders class include drowsiness, sedation, dizziness, and headache. No specific wider mental health or mood effects, such as anxiety or depression, are commonly listed in the regulatory summaries.

Q: Is Regeron-E Plus known to cause weight change?

The pharmacological component is classified as an appetite stimulant. This class of antihistamines is recognized for its property to stimulate appetite, and this effect is associated with potential weight gain.

Q: What does the drug's safety classification (e.g., Category X) mean for Regeron-E Plus?

Safety classifications (such as FDA Pregnancy Categories) are definitions used by regulatory bodies to describe the level of risk observed in human or animal studies. For example, Category X indicates that studies have demonstrated fetal risk and that the risks clearly outweigh any potential benefits.

This section details the official storage, handling, and disposal instructions for Regeron-E Plus Capsule, based on regulatory labeling.

Storage Conditions and Protection

Requirement	Description
Temperature Restriction	Store at a temperature not exceeding 30 C.
Light/Moisture	Must be protected from light and excess moisture.
Packaging Rule	Keep the capsules in the Original Amber Blister Pack until use.

Child Safety and Disposal

Requirement	Description
Child Protection	Keep out of the sight and reach of children due to the specific risk of accidental iron poisoning.
Disposal	Dispose of unused or expired product according to local regulations.

Regulatory documents define that the product must be stored under these specific environmental constraints to maintain stability. The disposal mandate requires the use of approved pharmaceutical waste channels, and the product must not be flushed down a toilet or poured into a drain.